Cases & Deals

  • Home
  • Practices
  • Alamar Biosciences develops global patent portfolios related to biopsy platform involving Next Generation Sequencing (NGS)

Share

Alamar Biosciences develops global patent portfolios related to biopsy platform involving Next Generation Sequencing (NGS)

June 2022

Client(s) Alamar Biosciences, Inc.

Jones Day is assisting Alamar Biosciences, Inc. with counseling and development of global patent portfolios related to a highly sensitive proteomic liquid biopsy platform involving Next Generation Sequencing (NGS).

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.